Basic Information
| LncRNA/CircRNA Name | FOXD1-AS1 |
| Synonyms | NA |
| Region | GRCh38_5:73446357-73446984 |
| Ensemble | ENSG00000247993 |
| Refseq |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | apoptosis | Drug | ||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | glioma |
| ICD-0-3 | NA |
| Methods | qRT-PCR, Western blotting, in vitro knockdown etc. |
| Sample | human glioma cell lines(U87, U251, U138, and Hs683) |
| Expression Pattern | up-regulated |
| Function Description | FOXD1-AS1 was upregulated and directly correlated with the glioma grade, and it was localized in both the nucleus and the cytoplasm of the glioma cell. FOXD1-AS1 silencing caused tumor suppressive effects via inhibiting cell proliferation, migration, and apoptosis, while FOXD1-AS1 overexpression resulted in opposite effects. Additionally, in vivo experiments showed that FOXD1-AS1 knockdown reduced tumor volume and weight. More importantly, FOXD1-AS1 targeted both miR339-5p and miR342-3p (miR339/342). Furthermore, protein eukaryotic translation initiation factor 5 subunit A (eIF5a) resulted a direct target of FOXD1-AS1. |
| Pubmed ID | 31102349 |
| Year | 2019 |
| Title | LncRNA FOXD1-AS1 acts as a potential oncogenic biomarker in glioma |
External Links
| Links for FOXD1-AS1 | GenBank HGNC NONCODE |
| Links for glioma | OMIM COSMIC |